Mundipharma and HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. (ShanZeBIO) jointly announced that the two companies have entered into a strategic licensing agreement for REZZAYO/XIUNIS (rezafungin acetate) in Mainland China, Hong Kong, and Macau — granting ShanZeBIO exclusive rights to register, develop, and commercialize the first second‑generation echinocandin antifungal, which enables once‑weekly dosing via an approximately 133‑hour half‑life for the treatment of candidaemia and invasive candidiasis in adults.
Partnership Snapshot
| Item | Detail |
|---|---|
| Licensor | Mundipharma |
| Licensee | HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. (ShanZeBIO) |
| Product | REZZAYO/XIUNIS (generic name: rezafungin acetate) |
| Agreement Type | Strategic licensing agreement |
| Licensed Territories | Mainland China, Hong Kong, and Macau |
| Rights Granted | Exclusive rights to register, develop, and commercialize |
| Commercial Responsibility | ShanZeBIO fully responsible for commercialization and promotion across the designated regions |
| Announcement Date | 28 Oct 2026 |
| Financial Terms | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Rezafungin (rezafungin acetate), marketed as REZZAYO/XIUNIS.
- First in Generation: The first second‑generation echinocandin antifungal drug, advancing the class that anchors treatment of serious Candida infections.
- Indication: Treatment of candidaemia and invasive candidiasis in adults.
- Pharmacokinetic Advantage: A half‑life of approximately 133 hours in humans enables once‑weekly dosing — a marked convenience improvement over daily intravenous echinocandin regimens.
- Expanded Investigation: Rezafungin is also being investigated for the prevention of invasive fungal disease in adult patients undergoing allogeneic hematopoietic stem cell transplantation (allo‑HSCT), a highly immunocompromised population at elevated fungal‑infection risk.
Disease Landscape – Invasive Candidiasis
- Critical Unmet Need: Invasive candidiasis remains a critical, unaddressed clinical challenge, particularly among hospitalized critically ill and immunocompromised patient populations.
- High Mortality: Despite the availability of various treatment options, the mortality rate for patients with invasive candidiasis remains as high as 40 %.
- Dosing Burden of Current Care: Existing echinocandin therapies typically require daily administration, complicating outpatient parenteral therapy, ward logistics, and care transitions — the gap once‑weekly rezafungin is designed to close.
- Transplant Prophylaxis Frontier: Patients undergoing allo‑HSCT face prolonged periods of profound immunosuppression, making extended‑interval antifungal prophylaxis an attractive investigational strategy.
Market Impact & Outlook
- Exclusive Regional Platform: The agreement hands ShanZeBIO the complete Greater China commercial pathway for rezafungin — registration, development, and promotion across Mainland China, Hong Kong, and Macau — leveraging its local hospital‑market infrastructure in anti‑infectives.
- Differentiated Antifungal: As the first second‑generation echinocandin, rezafungin brings a once‑weekly dosing proposition to a therapeutic area where daily infusions remain the standard of care.
- Large Addressable Population: China’s substantial critically ill and immunocompromised hospital populations, combined with up to 40 % mortality in invasive candidiasis, underscore the clinical and commercial significance of improved antifungal options.
- Lifecycle Expansion Potential: The ongoing allo‑HSCT prophylaxis investigation could broaden rezafungin’s label from treatment into prevention, materially extending its hospital‑based market opportunity.
- Watch Items: Registration submissions and regulatory review across the three territories, launch sequencing and hospital access in Mainland China, and clinical progress in the transplant‑prophylaxis setting.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic licensing agreement between Mundipharma and ShanZeBIO, including registration plans, regulatory approvals, commercialization timing, and the clinical investigation of rezafungin for invasive fungal disease prevention in allo‑HSCT patients. Actual results may differ due to risks including regulatory review outcomes in each territory, market adoption and reimbursement dynamics, clinical trial results, competitive pressures in antifungal therapy, and commercialization execution. Financial terms of the agreement have not been disclosed.-Fineline Info & Tech
